Intravenous Immunoglobulin for PANDAS

Key facts

Sponsor

National Institute of Mental Health (NIMH)

Principal Investigator

Susan E Swedo, M.D., M.D

National Institute of Mental Health (NIMH)

Intervention

Gamunex Intravenous Immunoglobulin(drug)

Enrollment

48 target

Eligibility

4-13 years · All sexes

Timeline

2011 – 2018

Study locations (1)

• National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for PANDAS

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06811935
  PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
  University of Wisconsin, Madison
• RECRUITINGNCT02889016
  Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
  Stanford University

See all trials for PANDAS →